Markus Warmuth
President, CEO & DirectorDr. Markus Warmuth, M.D., serves on Board of Directors of Ventus Therapeutics U.S., Inc. since December 7, 2021. He serves as President, Chief Executive Officer and Director at Monte Rosa Therapeutics, Inc. since January 2020. He served as a Venture Partner at Versant Venture Management, LLC from September 2019 to 2024. He was an Entrepreneur-In-Residence at Third Rock Ventures, LLC since July 2018 to August 2019. He focuses on the formation of new biotech companies. He serves as a Venture Partner at Versant and as Chief Executive Officer of Monte Rosa Therapeutics. He has several years of drug discovery experience and scientific acumen, with a strong focus on developing targeted therapy, immune-oncology program and precision medicine drug development expertise to the firm. Previously, he was the Chief Executive Officer and President of H3 Biomedicine Inc. since October 1, 2011 to May 2018. Dr. Warmuth joined H3 Biomedicine as Chief Scientific Officer in August 2011 to October 2011. Dr. Warmuth has significant experience in cancer biology, drug discovery and clinical oncology to H3. During his career as a pharmaceutical industry research executive, he has successfully built and shaped oncology research groups and portfolios. Prior to joining H3, Dr. Warmuth served as Head of Oncology Drug Discovery for the Novartis Institute for Biomedical Research (NIBR), Cambridge (U.S.) Site. There, he oversaw a significant part of NIBR’s global oncology drug discovery portfolio from target discovery to clinical development. At Novartis he and his teams were involved in the development of ceritinib and ribociclib as well as the discovery of allosteric inhibitors of SHP2 and Abl, amongst others. From 2002 to April 2008, Dr. Warmuth worked at the Genomics Institute of the Novartis Research Foundation (GNF), San Diego, where he served as Director of Kinase Biology and Head of the Oncology Pharmacology Program. He was a Director of Relay Therapeutics, Inc since April 4, 2017 to August 2019. Dr. Warmuth had been an Independent Director of IMV Inc., since November 6, 2018. Dr. Warmuth serves on the Scientific Review Board of the Starr Cancer Consortium. Dr. Warmuth studied and received his Doctorate in Medicine from the internal -Maximilians-University of Munich, Germany (1991-1998). He trained in Internal Medicine and Oncology at the University of Munich. From 1998 to 2002, he was a Principal Scientist with the “Clinical Cooperation Group Signaling” at the German National Research Center of Environment and Health (GSF), where he studied the mechanism of action and resistance to multiple small molecule kinase inhibitors in leukemia and lymphoma. He earned MD in Medicine from Ludwig Maximilian University during 1991-1998.
Positions
- Company NameMonte Rosa Therapeutics, Inc.Stock CodeGLUEPositionPresident, CEO & DirectorColleagues
- ANAndrew Newman SchiffIndependent Chairman of the Board
- PNPhilip NicksonChief Business & Legal Officer
- FJFilip JankuChief Medical Officer
- MBMatthew BowenCorporate Controller & Principal Accounting Officer
- JCJennifer ChampouxChief Operating Officer
- KLKimberly Lynn BlackwellIndependent Director
- CEChristine E. SiuIndependent Director
- JSJan SkvarkaIndependent Director
